EGFR and cancer: Third, this RTKs-targeting degradation strategy can be combined with antibodies or small molecule inhibitors against RTKs, especially when kinase-independent biologic functions of RTKs, such as IGF-1R and EGFR, also contribute to cancer malignancy [49].